Member Info for Energyshares

https://www.irishtimes.com/business/2022/12/12/amgen-said-to-agree-247bn-deal-for-horizon-therapeutics-bloomberg/

That will do I’ll take that bid. :):):)

If one of the majors did try and make a hostile bid for Avacta.
How the hell do they put a value on the Avacta licence agreements and IP

Pre/Cision platform
TMac platform
LG Chem licence
Point Bio Licence
Affyxell part ownership
Diagnostics Division and Launch.
Astrea Bioseparations licence
Affimer pipeline and patents

Hold for gold GLA

I think Big Pharma will beat the market to what’s going on here.
They will be watching this trial and a T/O and suspension will probably come before the re-rate.

Someone at Avacta loves this word:

https://www.ddw-online.com/t/avacta/

http://affyxell.com/en/

gmcc
The dosage is interesting as well Avacta putting nearly 3 x more dox into patients at
dose of AVA6000 at 200mg/m2.

Drug: TTI-621
TTI-621 will be administered by intravenous infusion.

Drug: Doxorubicin
75 mg/m2 by intravenous infusion on Day 1 of each 21-day cycle for a maximum of 6 cycles

HaHa Rippers
I do enjoy reading Rah and Tom Bomb on here and twitter but I don’t follow anyone on twitter

I did try the Happy Clapping Club on Telegram but once it went to a closed Church I gave that up.

GLA our RNS will come soon.

Pfizer have a doxorubicin trial at about the same stage as Avacta ongoing at Memorial Sloan Kettering
Both for Advanced Soft Tissue Sarcoma

https://www.mskcc.org/cancer-care/clinical-trials/21-407

Trillium received FDA ODD for the drug in 2018
then we’re bought out by Pfizer in 2021 for $2.2 billion

https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-acquisition-trillium-therapeutics

$2.2 billion x how many drugs in the pre/Cision platform. :):):):)

JT
Great thread
So Moderna worth $5billion MCap 2019
and now MCap is $69 billion
5 to 69 billion in 3 years with success of just a vaccine.

Avacta need to get on the NASDAQ with the shots on goal they have..

We are waiting on so much news, how is AS going to put it all in one RNS

PK Data
Science day
P1a completed
P1b started
Licence agreement AVA3996
Diagnostics update

Could they all come in one RNS

Could big Pharma be looking over the data now and a RNS share suspension T/O offer to share holders be on the cards.

Exciting few weeks ahead

GLA

Great find Gadgie :)

I think C5 theory is finished now, the new hospital will be used for 1b .
Like Rippers said it’s probably just data gathering.
1b finish date hasn’t moved on the clinical trial site so they should announce 1b has started if it hasn’t already soon.
GLA

Don’t know if this has been posted before but very interesting :
I like this,got to be Affyxell

Some of our unpublished results have generated commercial interest and investment in the Affimer brand which recently helped Avacta fund raise for a therapeutic programme.

Some of the Affimers generated in our laboratory for Avacta Life Science are available to purchase and we regularly screen targets for Avacta's industrial collaborators and clients. Some of our unpublished results have generated commercial interest and investment in the Affimer brand which recently helped Avacta fund raise for a therapeutic programme, some of which will be fed back into the academic projects at Leeds. This demonstrates our drive to develop impact through the Affimer technology. This porfolio of collaborators is only likely to grow after publication of the ability to directly label proteins providing further impact for our research.

https://gtr.ukri.org/project/B62E4643-BE4E-42AC-9AD0-A659947F2584

It’s the latest we have not 2021

RNS Number : 0770B
Avacta Group PLC
29 September 2022

in August 2022, the third cohort was completed and the SDMC approved dose escalation to 200mg/m2 in the fourth cohort which is now recruiting patients in the UK. The fourth cohort is expected to be completed during Q4 2022.

Roll on the football

It’s not a diagnostic device,
The trial is with very poorly,very frail and courageous patients have some compassion they are fighting for their lives and you can’t wait 6 months to start your next trade position.

It takes as long as it takes
Get a grip wynbag

RNS Number : 0770B
Avacta Group PLC
29 September 2022

in August 2022, the third cohort was completed and the SDMC approved dose escalation to 200mg/m2 in the fourth cohort which is now recruiting patients in the UK. The fourth cohort is expected to be completed during Q4 2022.

No delay here…..
Attention seeker

“ Bein... tell me how Avacta fund P2 please if they are to retain 100%...”

I think Avacta will take it to end of 1b and get a major as a partner to fund P2 and bring it to market with Avacta owning 50% a lot more than licening out.
That’s the only way they could get it on the market ASAP.

Sorry don’t know where those question marks came from :)

On the twelfth day of Christmas
?Big Al sent to me?
Twelve months of waiting ?
Eleven Cancer targets?
Ten Bagger dreaming
Nine Months since the poster data?
Eight shots with LG Chem?
Seven AM waking & waiting?
Six Hospitals trialing?
Five Golden RNS’s please?
Four Muppets crying daily?
Three Dose Escalations
?Two Divisions scaling?
And a RNS with it bloody works please.

EGTP,RAH great posts

Imagine asking for £55 million loan to buy and expand a diagnostic business.

“ But you had had the best LFD in the world in covid and never sold a bean why should you lend to buy Launch and expand”

Look at this data on our lead drug AVA6000 and we also have AVA3996 ready to licence with deal done worth “X” amount once we release data.

OK is £55 million enough :):):)

Could Avacta be waiting on FDA clinical trial award.

Clinical trial grants for orphan products are a proven method of successfully fostering and encouraging the development of new safe and effective medical products for rare diseases and conditions. The FDA’s Office of Orphan Products Development (OOPD) awards new clinical trial grants annually. A major portion of appropriated funds for a given fiscal year provides continued funding of ongoing awards. There are typically 60 to 85 ongoing grant projects every year. OOPD awards approximately five to twelve new grants each year, as resources allow. The rapid increase in the cost of clinical trials in recent years has precluded an increase in the number of new grants. OOPD conducts ongoing grant evaluations to ensure extramural funded studies maintain grant agreement terms and minimize risk to people participating in the clinical research.

11 granted this year so far big chunk of trial costs received through these grants, make sense to wait.

https://www.fda.gov/industry/clinical-trial-and-natural-history-study-grants